Validated Skin Irritation Study Confirms Ion Gel ZCM-25® Is Non-Irritant at High Dose

A comprehensive study conducted in 2018 by CIATEJ (Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco) has confirmed that Ion Gel ZCM-25® is non-irritating to the skin—even at five times the standard human application dose. The study was carried out under rigorous preclinical standards, using a rabbit model to simulate extreme exposure conditions and determine whether the topical formulation could provoke adverse dermal responses.

This study plays a critical role in validating the product’s safety for dermatological and medical use, including in populations with sensitive, damaged, or healing skin. When a topical formulation is intended for use on wounds, ulcers, or post-operative skin, ensuring non-irritancy is essential. The outcome of this investigation adds to the growing body of data supporting Ion Gel ZCM-25®'s tolerability and safety.

Skin Irritation Study Overview and Methodology

The objective of the study was to evaluate the local tolerability of Ion Gel ZCM-25® under conditions designed to stress the dermal barrier. Using healthy rabbits, a single high-concentration dose was applied to intact skin areas and monitored for visible signs of irritation over time.

Protocol Summary:

• Animal model: Healthy rabbit
• Application area: 6.25 cm² (clipped, intact skin)
• Dose used: 0.5 mL (5× the human equivalent dose)
• Duration: Observed over a standard 72-hour window
• Parameters monitored: Presence or absence of erythema (redness) and edema (swelling)

Results:

• No erythema observed
• No edema detected
• No behavioral signs of discomfort
• No residual or delayed irritation at the application site

The product was thus officially classified as Non-Irritant under the Globally Harmonized System (GHS) safety classification standards.

Importance of This Study

In the field of topical medical devices and dermo-cosmetic treatments, a validated study is not optional—it is foundational. Regulatory agencies like COFEPRIS, EMA, and FDA require non-clinical testing data demonstrating the absence of irritant effects before approving any product for clinical trials or widespread medical use.

This study adds critical preclinical evidence to the dossier of Ion Gel ZCM-25® and is part of a robust safety validation program that includes:

• Human Phase I tolerability trials (UNAM, 2020)
• Repeat-dose irritation studies (UNIPREC, 2019)
• MTT in vitro cytotoxicity testing using human keratinocyte (HACAT) cell lines

Each of these studies complements the findings from the original skin irritation study, confirming that Ion Gel ZCM-25® is safe even at elevated doses and under repeated applications.

Scientific Context: Why Skin Irritation Testing Is Essential

The study is one of the most direct ways to evaluate whether a topical formulation can be used safely in real-world clinical scenarios. Skin, particularly when damaged or recovering, is more vulnerable to chemical stress. In wound care, oncology, and post-surgical applications, any additional irritation can:

• Delay healing
• Disrupt skin barrier function
• Exacerbate inflammation
• Reduce patient adherence due to discomfort

Thus, a formulation’s ability to avoid irritation—especially when dosed at multiple times the human equivalent—is not just a regulatory checkbox, but a core therapeutic requirement.

Ion Gel ZCM-25® Formulation Details Relevant to the Skin Irritation Study

The formulation used in the study contains the following key elements, all optimized to reduce dermal stress:

• Zn²⁺, Cu²⁺, and Mg²⁺ ions: These promote redox balance and tissue regeneration
• Hydronium ion buffering system: Maintains a mildly acidic pH suitable for wound beds
• Sodium hyaluronate: Supports hydration and barrier reinforcement
• Sepineo Derm: A novel dermatological polymer that reduces transdermal water loss

These components are part of the IBAL (Ion Biotechnology Aqueous Ligands) technology platform, which is engineered for high skin bioavailability with low irritation potential.

Skin Irritation Study Supports Use in Sensitive and At-Risk Skin

The excellent results from this study justify the use of Ion Gel ZCM-25® across a variety of clinical settings:

1. Post-Surgical Care

• After surgical incisions, the skin is in a reactive state. A non-irritant formulation is essential for aiding recovery and preventing complications such as dermatitis or delayed wound closure.

2. Chronic Ulcers and Bedsores

• In diabetic patients or the elderly, ulcers present a significant clinical challenge. The safety margin shown in the skin irritation study confirms that Ion Gel ZCM-25® is safe even in fragile tissue environments.

3. Dermatitis or Reactive Skin Disorders

• Patients with eczema, contact dermatitis, or autoimmune dermatoses often react negatively to topical therapies. A formulation proven through a rigorous irritation study reduces the risk of flare-ups or sensitization.

4. Pediatric and Geriatric Dermatology

• These populations typically have thinner skin and are more prone to irritant responses. Demonstrating safety in a preclinical skin irritation study is a strong predictor of tolerability in these groups.

Complementary Safety Testing and Broader Evidence

The skin irritation study performed at CIATEJ is not isolated—it fits into a broader framework of evidence. Supporting data includes:

• Phase I Clinical Trial in Humans (UNAM)
  • 20 volunteers received daily applications for 14 days
  • No skin irritation, systemic toxicity, or side effects observed
• Repeat Application Rabbit Study (UNIPREC)
  • Longitudinal study with reapplication of high-dose Ion Gel
  • No adverse dermal reactions even under occlusion
• MTT Cytotoxicity on HACAT Cell Line
  • Assesses intracellular viability and membrane integrity
  • Ion Gel ZCM-25® demonstrated low cytotoxicity at therapeutic doses

Together, these studies reinforce the conclusions of the original study: Ion Gel ZCM-25® has a clean safety profile for dermal use.

Visual Summary of the Study

Parameter	Result
Model	Rabbit
Dose	0.5 mL (5× human equivalent)
Application Area	6.25 cm²
Observed Erythema	None
Observed Edema	None
Classification (GHS)	Non-Irritant
Lab	CIATEJ Biotechnology Unit

This summary makes the safety profile easy to communicate across clinical and regulatory teams.

Why This Study Matters in a Clinical Landscape

More than ever, topical products are being developed to address chronic, inflammatory, and immunocompromised skin conditions. In these contexts, even minor irritant effects can have disproportionate consequences.

The skin irritation study validates Ion Gel ZCM-25® as a product that clinicians can trust—not only for efficacy but also for minimizing the risk of additional skin damage during treatment.

This becomes even more critical in hospital and outpatient settings where:

• Infection control is a priority
• Skin integrity is already compromised
• Adherence and comfort directly impact outcomes

Conclusion

This validated skin irritation study confirms that Ion Gel ZCM-25® is dermally safe even at doses far above standard use, supporting its role as a next-generation solution in topical therapy. Its high-dose tolerability, clean classification under GHS, and absence of irritation make it an ideal choice for sensitive skin applications, from post-surgical sites to chronic wound care.

As clinical adoption expands, this safety foundation ensures that Ion Gel ZCM-25® continues to meet the highest standards of dermatological integrity and patient trust.

Learn More

Full safety documentation and technical reports available at:
https://zcm25.com/resources